XSHG
600538
Market cap418mUSD
Jul 10, Last price
5.27CNY
1D
-2.59%
1Q
-21.23%
Jan 2017
-61.36%
IPO
-2.13%
Name
Beihai Gofar Chuanshan Biological Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beihai Gofar Chuanshan Biological Co., Ltd., together with its subsidiaries, engages in the distribution of pharmaceutical products in China. It operates through Pharmaceutical Distribution [Industry]; Pharmaceutical Manufacturing; DNA Testing Equipment, Consumables and Testing Services; and Others segments. The company wholesales and retails various medicines and medical devices through directly operated and franchised chain drugstores. It also provides pearl eye drops, pearl powder, and pearl layer powder under the Haibao brand; weichangning granules under the Guofa brand; ethanol disinfectant; honeysuckle mixture; feier syrup; medicinal wine for traumatic injury under the Hippocampus brand; and sea snake medicinal wine. In addition, the company offers forensic DNA testing equipment, reagents, and consumables; and technical services, including DNA testing services. Further, it engages in culture and arts activities. The company was formerly known as Beihai Gofar Marine Biological Industry Co., Ltd. and changed its name to Beihai Gofar Chuanshan Biological Co., Ltd. in June 2021. Beihai Gofar Chuanshan Biological Co., Ltd. was incorporated in 1993 and is headquartered in Beihai, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||